SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending following preliminary positive clinical data for its GLSI-100 immunotherapy, showing an 80% reduction in breast cancer recurrence rates. This, combined with the company's board extending insider share lock-ups until 2026, signals strong confidence and is fueling fervent community discussion around a potential short squeeze, given the extremely high cost to borrow and limited available shares.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano ($ADA) is currently a hotbed of intense community FUD, with many investors vehemently labeling it a 'scam' and predicting significant 'rugpulls' and 'dumps,' largely blaming its founder Charles Hoskinson. Despite widespread bearish sentiment suggesting the project is 'dead,' a smaller segment is actively accumulating, anticipating a future market resurgence or positive legislative impact like a 'Clarity Act' run. The pervasive negative sentiment, fueled by perceived price underperformance, is the immediate catalyst driving conversation around $ADA.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is experiencing intense trading activity amidst a sharp price pullback, largely attributed to increased margin requirements by a major commodities exchange triggering forced liquidations. Investors are fiercely debating whether this represents a "buy the dip" opportunity, fueled by concerns over looming export restrictions from a key global consumer and persistent supply/demand imbalances, or if it signals an unsustainable top after a parabolic ascent. This market action underscores the deep divide between perceived paper market manipulation and the fundamental outlook for physical silver.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital is trending amidst significant year-end tax-loss harvesting, with the community expressing widespread frustration over its notable underperformance and perceived management issues, particularly regarding share dilution. Despite the stock trading at a discount to its Bitcoin holdings, proponents highlight its strategic pivot into AI/HPC data centers and substantial short interest as potential catalysts for a rebound.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical is trending after its setrusumab drug for osteogenesis imperfecta failed to meet primary endpoints in late-stage trials, prompting a significant stock decline. The community is actively debating whether this represents an overreaction, pointing to the company's existing approved products and deep pipeline as reasons for a potential rebound.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending due to robust demand for AI-driven memory solutions, with reports indicating rising HBM prices and a strong outlook for supply shortages extending into 2026. The community is actively discussing Micron's perceived undervaluation despite its impressive growth and leadership in the critical AI memory sector, while some express caution about the rapid ascent. This narrative has led to a highly bullish sentiment, with many anticipating continued strength as memory becomes a crucial constraint and differentiator in modern AI systems.

TryHard Holdings Ltd. is a lifestyle entertainment company that operates in Japan offering a diverse range of services across the entertainment and hospitality sectors. It operates through the following business segments: Consultancy and management, Event curation, Sub-leasing and Restaurants. The Consultancy and management segment provides expert services to clubs, including operations, event management, and strategic support to enhance performance and engagement. The Event curation segment organize and produce own events, also provides a full suite of services, including event planning, construction, entertainment booking, event operation, and ticket sales. The Sub-Leasing segment acts as an intermediary between landlords and clubs. The Restaurants segment operates several restaurants. The company was founded on October 16, 2013 and is headquartered in Osaka, Japan.

TryHard Holdings Ltd.

TryHard Holdings Ltd. ($THH) is a top trending stock following its recent Initial Public Offering (IPO) on NASDAQ, with community discussion centered on its high volatility as a low-float play. While some investors are optimistic about its significant price appreciation potential, others are highly skeptical, raising concerns about its dramatic price swings and labeling it as a potential "pump and dump."

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is drawing significant attention with upcoming CES 2026 as a potential catalyst for new partnerships, alongside recent analyst upgrades pointing to its leading voice AI technology. While many investors highlight the company's strong fundamentals, including a substantial contractual backlog and no debt, community dialogue is split between optimism for a rebound and concerns over recent insider selling.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to a series of positive regulatory updates and clinical trial results, with community speculation centered on its undervalued status and significant pipeline potential. Recent highlights include a favorable appeals court ruling on Hetlioz for jet lag and promising data for tradipitant in mitigating GLP-1 induced nausea, which could unlock a massive market. Traders are actively discussing multiple upcoming regulatory decisions and potential acquisition interest, positioning the stock for a pivotal period.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is currently capturing significant attention, driven by enthusiastic discussions around the impending LitVM airdrop and the launch of its Omnichain system, which introduces new yield-earning capabilities. The community is actively debating strong bullish prospects and favorable technical indicators, reinforcing its long-held narrative as "digital silver" within the broader crypto market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3% - Should You Sell?

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3% - Time to Sell...

Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?

Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

<ul class="summary-bullets"><li>The list included companies from healthcare, consumer, and banking.</li><li>The stocks were among the most discussed names during the Christmas Eve session.</li><li>Trading took place during a shortened U.S. market session.</li></ul>U.S. stocks finished the shortened Christmas Eve session on a firm footing, with the S&amp;P 500 touching a fresh record as investors leaned into expectations for interest-rate cuts in the year ahead.&nbsp;Optimism was supported by data showing the U.S. economy expanded at its fastest pace in two years during the third quarter, while a drop in new jobless claims on Wednesday pointed to continued resilience in the labor market.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was up 0.5% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, gained 0.3%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, rose 0.6%.<h3 class="st-heading-3">Here’s a look at the names that drew the most buzz:</h3><h2 class="st-heading-2">Omeros Corporation (OMER)</h2>Omeros surged 67% in Wednesday’s midday session following its long-awaited&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/omeros-stock-jumps-premarket-after-fda-approves-first-drug-for-rare-transplant-complication/cLesxhYREvL">FDA approval for Yartemlea</a>, the first and only treatment approved for the rare and often-fatal transplant complication TA-TMA. The green light paves the way for a U.S. launch in the first half of next year.<a href="https://stocktwits.com/symbol/OMER">OMER stock</a> is up 69% year-to-date.<h2 class="st-heading-2">Nike (NKE)</h2>Nike climbed 5% in Wednesday’s midday session after a regulatory filing showed board member&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nike-stock-pops-after-hours-as-apple-s-tim-cook-buys-nearly-3-m-in-shares-amid-turnaround-effort/cLeqcjTREHl">Tim Cook made a nearly $3 million</a> open-market purchase of the stock. The buy stood out as a show of confidence as the company navigates a multi-year turnaround under returning CEO Elliott Hill, even as tariffs and a cautious holiday outlook continue to weigh on sentiment.<a href="https://stocktwits.com/symbol/NKE">NKE stock</a> is up 5% year-to-date.<h2 class="st-heading-2">Citigroup (C)</h2>Citigroup rose 2% in Wednesday’s midday session and extended a powerful rally, pushing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/citi-stock-hits-highest-levels-since-2008-factors-at-play/cLetR7ZREvo">shares to levels last seen since 2008</a>. The stock has logged gains in most recent sessions as investors responded to upbeat brokerage calls, easing regulatory pressure and a sweeping internal overhaul aimed at boosting returns and simplifying the business.C<a href="https://stocktwits.com/symbol/NVO"> stock</a> is up 2% year-to-date.<h2 class="st-heading-2">Dynavax Technologies (DVAX)</h2>Dynavax jumped 38% in Wednesday’s midday session after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-dynavax-stock-surge-38-in-premarket-today/cLesA4mREHU">Sanofi agreed to buy the vaccine maker</a> for $2.2 billion in cash. The deal adds Dynavax’s hepatitis B vaccine and pipeline assets to Sanofi’s portfolio and marked one of the day’s clearest takeover-driven moves.<a href="https://stocktwits.com/symbol/DVAX">DVAX stock</a> is up 38% year-to-date.<h2 class="st-heading-2">Agios Pharmaceuticals (AGIO)</h2>Agios rallied 18% in Wednesday’s midday session after the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-agio-stock-surge-14-today/cLesxI9REvh">FDA approved Aqvesme</a>, an oral therapy for anemia in adults with alpha- or beta-thalassemia. The approval, backed by late-stage trial data, positions Aqvesme as the only FDA-approved treatment across both transfusion-dependent and non-dependent forms of the disease, with a U.S. launch expected next month.<a href="https://stocktwits.com/symbol/AGIO">AGIO stock</a> is up 18% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

With holiday festivities officially beginning in New York with the Thanksgiving Day Parade on Thursday, Santa Claus and elves visited the New York Stock Exchange (NYSE) on November 26, 2025. (Photo by Spencer Platt/Getty Images)

Retail’s Christmas Eve Watchlist: Omeros, Nike, Citi, Dynavax And Agios Spark Most Market Chatter

The stocks were tracked during the shortened Christmas Eve session across healthcare, consumer, and banking.

Equity

Truist Financial Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Truist Financial increased their price objective on Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a "buy" rating in a report on Wednesday...

Here's Why Shares in Agios Pharmaceuticals Popped Today

Key PointsThe new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant...

AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label

Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Analyst Upgrade

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Analyst Upgrade...

<ul class="summary-bullets"><li>BofA raised AGIO’s price target to $34 from $32, while maintaining a ‘Buy’ rating, according to The Fly.</li><li>The approval is based on results from the global Phase 3 ENERGIZE and ENERGIZE-T trials, which involved 452 patients.</li><li>Agios expects AQVESME to be available in the U.S. by late January 2026.</li></ul>Shares of Agios Pharmaceuticals (AGIO) jumped 14% on Wednesday after the U.S. Food and Drug Administration (FDA) approved its oral therapy for anemia in adults with alpha- or beta-thalassemia, an inherited blood disorder.The FDA approval also prompted BofA to raise AGIO’s price target to $34 from $32, while maintaining a ‘Buy’ rating, according to The Fly. According to the company, AQVESME oral therapy is currently the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent forms of thalassemia.<h2 class="st-heading-2">AQVESME Test Details</h2>The approval is based on results from the global Phase 3 ENERGIZE and ENERGIZE-T trials, which involved 452 patients. Across both studies, AQVESME met all primary and key secondary endpoints, with improvements in hemolytic anemia and quality of life compared with placebo. Patients treated with AQVESME showed significant increases in hemoglobin levels, reduced transfusion burden, and improved fatigue.During the trials, five patients receiving AQVESME experienced adverse reactions suggestive of hepatocellular injury (HCI), with two of them requiring hospitalization. These events occurred within the first six months of treatment and resolved after stopping the drug.To manage this risk, the FDA approved AQVESME with a Risk Evaluation and Mitigation Strategy (REMS) program, which includes regular liver testing. Agios expects AQVESME to be available in the U.S. by late January 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment shifted to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes. AGIO was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/AGIO_png_462a9335f9.webp" alt="AGIO.png">One user sees accumulation but wants higher trading volumes to confirm demand.<stembedurl>https://stocktwits.com/MacroTrackX_1534/message/640057716</stembedurl>Year-to-date, AGIO stock has declined 25%.&nbsp;&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-omeros-stock-surging-fda-verdict-this-week/cLesvbHREv7">Omeros Stock Garners High Retail Attention Ahead Of FDA Verdict For Life-Saving Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Agios Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did AGIO Stock Surge 14% Today?

Shares of Agios Pharmaceuticals (AGIO) jumped 14% on Wednesday after the U.S. Food and Drug Administration (FDA) approved its oral therapy for anemia in adults.

Why Did AGIO (Agios Pharmaceuticals) Stock Surge 14% Today?

Agios Pharmaceuticals announced that the FDA approved its oral therapy for anemia in adults with alpha- or beta-thalassemia.

Bank of America Issues Positive Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price

Bank of America upped their price objective on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a "buy" rating in a report on Wednesday...

<ul class="summary-bullets"><li>Retail sentiment turned bullish on SPY, even as Nasdaq-linked QQQ remained under pressure on Stocktwits.</li><li>Investors bracing for low volumes and an early market close, even as fresh GDP data offered a bullish macro backdrop.</li></ul>U.S. stock futures traded cautiously early Wednesday, as markets prepared for a thin, holiday-shortened Christmas Eve session. Tuesday saw a record-setting close, supported by third-quarter GDP data, which was revised upward to a 4.3% annualized growth, significantly higher than the 3.2% consensus.&nbsp;As of 3:20 a.m. ET on Wednesday, Nasdaq 100 futures, S&amp;P 500 futures were flat, while the Dow futures fell 0.1% and the Russell 2000 futures were down 0.2%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, had moved to ‘bullish’ from ‘neutral’ a day ago. While sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, remained ‘bearish’ on Wednesday, amid high message volumes.Trading Holiday Schedule&nbsp;<ul><li>Equities Close: 1:00 PM ET today.</li><li>Bond Markets Close: 2:00 PM ET today.</li><li>Thursday, Dec 25: All U.S. markets are closed for Christmas Day.</li></ul><h2 class="st-heading-2">Trending Stocks To Watch</h2>Alphabet (GOOGL): Waymo said it will update its software used in self-driving vehicles following a high-profile fleet stall in San Francisco. AST SpaceMobile (ASTS): Successfully launched its "BlueBird 6" satellite, the largest commercial communications array ever put into orbit. Also, keep an eye on space-related stocks, such as Starfighters Space Inc. (FJET), which have been in the news this week.&nbsp; Dynavax (DVAX): Shares of Dynavax are in the spotlight following news that pharma giant Sanofi will acquire the vaccine maker to expand its vaccine portfolio in a $2.2 billion deal. Agios Pharmaceuticals Inc. (AGIO): The US FDA has granted approval to the company for AQVESME (mitapivat) for the treatment of anemia in adults who have alpha- or beta-thalassemia. Abivax (ABVX): This stock is catching retail attention amid reports that Eli Lilly met with French officials about a possible M&amp;A deal.&nbsp; Ramaco Resources (METC):&nbsp;In after-hours trading, the board authorized a $100 million stock repurchase program. UiPath (PATH):&nbsp;Gaining traction after S&amp;P Dow Jones Indices announced its admission into the S&amp;P MidCap 400, effective before the year ends. Other noteworthy tickers trending on Stocktwits at the time of writing were Medical Properties Trust (MPW), Critical Metals (CRML) &amp; Churchill Capital X (CCCX).<h2 class="st-heading-2">Other Catalysts To Track</h2>On the economic front, traders&nbsp;will keep an eye out for weekly jobless claims.<ul><li>Initial Jobless Claims (8:30 AM ET)</li><li>EIA Crude Oil Inventories (10:30 AM ET)</li></ul>The light earnings calendar today includes Bright Minds Biosciences (DRUG) and Scully Royalty (SRL).For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nasdaq, S&P 500 Futures Head Into Christmas Eve With Caution: Why ASTS, DVAX, ABVX, PATH, GOOGL Are On Traders' Radar Today

Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session. 

Is The Stock Market Open On Christmas Eve? US Futures Signal Muted Half-Day For Wall Street

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

AGIO
Agios Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AGIO News

AGIOAgios Pharmaceuticals Inc